Kyprolis is about a $800m/year product right now, and that's without any convincing trial showing superiority over Velcade. So I think this new trial should produce some growth.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.